PhaseRx completed a recent IPO backed by strong venture funds to limited fanfare.
Investors can buy the early-stage biotech at prices equal to or below where the insiders bought in the IPO.
The company offers interesting therapy candidates targeted at unmet needs with urea cycle disorders.
The stock is a high-risk biotech only appropriate for investors willing to assume the risk that these therapies never reach the market.
The recent slump in the IPO market and lack of attention to the sector typically provides opportunity when new stocks hit the market. The market has a history of over- and under-investing in different markets, from private companies to IPOs.